Our researchers have developed commercialisation opportunities in a range of fields, including new medical treatments, diagnostic assays, and a game to aid physiotherapy and rehabilitation.
We're looking for commercial partners to take these opportunities to market.
ARU welcomes the recommendations of the Independent Review of University Spinout Companies which will provide an opportunity to develop our policies and practice on spin-out creation.
The recommendations of the review will enable us to:
Explore opportunities below.
A screening service available from ARU can identify anti-fibrotic activity of novel small molecules and biologicals.
We have a suite of PCR assays available for licensing. They're robust, specific, simple and sensitive assays to identify a range of common fungal and antibiotic-resistant infections.
Work with us on a cost-effective rehabilitation game that improves the range of motion and the kinematic ability of motor-impaired participants. Use for physiotherapy purposes at home or in community settings.
Our researchers have identified a potential new treatment for cancer. We're seeking a commercial partner to develop the use of sucralose as a cancer treatment.
We've identified a potential new treatment for fibrotic diseases using two generic compounds, giving the potential for a new combination therapy.
Based in ARU’s state-of-the-art Science Centre in Cambridge, ARU Biometrics apply biomedical science technologies to solve your problems. Available resources include the Applied Extracellular Vesicle Research Laboratory, Immune Checkpoint Assays, Inflammation Biology, the Platelet Function Laboratory and Workplace drug testing.
Contact our Research and Innovation Development Office to discuss these opportunities.